Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VASCAMY

Financiado

Cerrado

Vascular and Aymloid Predictors of Neurodegeneration and Cognitive Decline in No...

Vascular and Aymloid Predictors of Neurodegeneration and Cognitive Decline in Nondemented Subjects "Alzheimer’s disease (AD) is the most frequent cause of dementia that affects one in 14 persons over the age 65 years and one in six persons over the age of 80 years. Increased deposition of the protein beta-amyloid (Aß) is a core... ver más

31/08/2017

LMU MUENCHEN

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

LMU MUENCHEN

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PSI2012-38257 INDICES DE PLASTICIDAD CEREBRAL REGIONAL COMO BIOMARCADORES... 70K€ Cerrado

SAF2011-25463 CARACTERIZACION DEL DETERIORO COGNITIVO EN LAS FASES PRESINT... 182K€ Cerrado

RTC-2016-5186-1 Control objetivo del deterioro cognitivo mediante análisis d... 494K€ Cerrado

TRACE-AD Tracking the Effects of Amyloid and Tau Pathology on Brain S... 192K€ Cerrado

CTQ2014-59544-P UNA PERSPECTIVA ATOMISTICA DE LA DETECCION, TOXICIDAD Y AGRE... 143K€ Cerrado

NOMAD Network Neurodegeneration in Alzheimer s Disease 270K€ Cerrado

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Alzheimer’s disease (AD) is the most frequent cause of dementia that affects one in 14 persons over the age 65 years and one in six persons over the age of 80 years. Increased deposition of the protein beta-amyloid (Aß) is a core brain pathology of AD that occurs years before the onset of clinical symptoms of dementia. Together with Aß, cerebrovascular disease, visible as on a MR image as white matter abnormalities, frequently co-occurs. A major question is whether Aß and cerebrovascular disease independently from each other predict disease progression and cognitive decline. The overall goal of the combined amyloid PET and MRI study is to assess how Aß pathology and vascular white matter damage contribute to cognitive decline through particular neuronal networks at an early stage of the disease. To this end, we will assess in a prospective 4-year longitudinal neuroimaging study 80 subjects with mild cognitive impairment (MCI) of episodic memory or executive function and 50 elderly cognitively healthy subjects (HC). Brain changes in association with Aß (florbetaben PET) and white matter degeneration (MRI, DTI) will be assessed in two major networks 1) temporo-parietal network that is typically associated with episodic memory, and 2) a subcortical-prefrontal network that is typically associated with executive function. Specifically, florbetaben PET binding and volumes of WMH and lacunes at baseline will be tested as predictors of fiber tract degeneration (DTI) and grey matter atrophy of those networks and cognitive decline during annual follow-up assessments. We expect that the results of this study will provide us with a clear understanding of the joint effects of the Aß and vascular white matter pathology on brain degeneration to predict cognitive decline during an early disease stage. This will help to identify subjects at risk of developing eventually dementia and will provide endpoints for clinical trials of disease modifying drugs to prevent dementia."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores